Merck downgraded by Truist with a new price target
$MRK
Biotechnology: Pharmaceutical Preparations
Health Care
Truist downgraded Merck from Buy to Hold and set a new price target of $110.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/18/2025 | $128.00 → $105.00 | Buy → Hold | Deutsche Bank |
| 2/10/2025 | $121.00 → $100.00 | Buy → Hold | TD Cowen |
| 1/8/2025 | $110.00 | Buy → Hold | Truist |
| 12/20/2024 | $136.00 → $105.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/10/2024 | $121.00 | Buy | BofA Securities |
| 12/4/2024 | $130.00 | Hold → Buy | HSBC Securities |
| 11/15/2024 | Peer Perform | Wolfe Research | |
| 11/11/2024 | Buy → Neutral | Daiwa Securities |
EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the European Commission (EC) has approved CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F and 35B in individuals 18 years of age and older. CAPVAXIVE is a pneumococcal vaccine specifically designed to help protect adults from the serotypes responsible for the majority of invasive pneumococ
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. ("Hengrui Pharma"), a global pharmaceutical company focused on scientific and technological innovation, today announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250325260661/en/ "Elevated blood concentrations of Lp(a) provides a well-documented risk factor for atherosclerotic cardiovascular
Approval is based on the Phase 3 KEYNOTE-868/NRG-GY018 Trial KIRKLAND, QC, March 19, 2025 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with carboplatin and paclitaxel, followed by KEYTRUDA® as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. The approval is based on data from the Phase 3 KEYNOTE-868 trial, also known as NRG-GY018, which demonstrated statistically significant improvements in progression-free survival (PFS) for patients randomized to KEYTRUDA® in combination with chemot
SCHEDULE 13G/A - Merck & Co., Inc. (0000310158) (Subject)
10-K - Merck & Co., Inc. (0000310158) (Filer)
13F-HR - Merck & Co., Inc. (0000310158) (Filer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov
WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023. Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India. As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annua
Replay Appoints Arun Balakumaran M.D., Ph.D as Chief Medical Officer Arun Balakumaran M.D., Ph.D, appointed Chief Medical Officer of Replay to support the Company's genomic medicine and engineered NK cell therapy pipelineFormer Chief Medical Officer of allogeneic CAR-T cell company Allogene Therapeutics and seasoned industry immuno-oncology, and cell and gene therapy expert Dr. Balakumaran also appointed CMO of Syena, Replay's engineered NK cell therapy product company pioneering first-in-class engineered T-cell Receptor Natural Killer cell (TCR-NK) therapy San Diego, California and London, UK, May 18, 2023 – Replay, a genome writing company reprogramming biology by writing and deliver
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
SC 13G/A - Merck & Co., Inc. (0000310158) (Subject)
Fourth-Quarter Worldwide Sales Were $15.6 Billion, an Increase of 7% From Fourth Quarter 2023; Excluding the Impact of Foreign Exchange, Growth Was 9% Fourth-Quarter GAAP EPS Was $1.48; Non-GAAP EPS Was $1.72; GAAP and Non-GAAP EPS Include a Charge of $0.23 per Share Related to Certain Business Development Transactions Full-Year Worldwide Sales Were $64.2 Billion, an Increase of 7% From Full Year 2023; Excluding the Impact of Foreign Exchange, Growth Was 10% KEYTRUDA Sales Grew 18% to $29.5 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 22% WINREVAIR Sales Were $419 Million Animal Health Sales Grew 4% to $5.9 Billion; Excluding the Impact of Foreign Exchange, S
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has declared a quarterly dividend of $0.81 per share of the company's common stock for the second quarter of 2025. Payment will be made on April 7, 2025, to shareholders of record at the close of business on March 17, 2025. The Board also authorized an additional $10 billion of treasury stock purchases with no time limit for completion. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope
Merck (NYSE:MRK), known as MSD outside of the United States and Canada, will hold its fourth-quarter and full-year 2024 sales and earnings conference call with institutional investors and analysts at 9:00 a.m. ET on Tuesday, Feb. 4. During the call, company executives will provide an overview of Merck's performance for the fourth quarter and outlook for 2025. Investors, journalists and the general public may access a live audio webcast of the call via this weblink. A replay of the webcast, along with the sales and earnings news release, supplemental financial disclosures and slides highlighting the results, will be available at www.merck.com. All participants may join the call by dialin
4 - Merck & Co., Inc. (0000310158) (Issuer)
4 - Merck & Co., Inc. (0000310158) (Issuer)
Deutsche Bank downgraded Merck from Buy to Hold and set a new price target of $105.00 from $128.00 previously
TD Cowen downgraded Merck from Buy to Hold and set a new price target of $100.00 from $121.00 previously
Truist downgraded Merck from Buy to Hold and set a new price target of $110.00